Deepson Bio Honored with Presidential Award for Innovative dementia Treatment Technology
Seoul, South Korea – December 5, 2025 – Deepson Bio co., Ltd. has been awarded the President’s Award, the highest honor at the ‘2025 Korea Invention Patent Exhibition,’ for its groundbreaking ultrasound-based technology targeting dementia. The company received the prestigious award on December 3rd.
The Korea Invention Patent competition, hosted by the Ministry of Intellectual Property and organized by the korea Invention Promotion Association, is the nation’s largest event recognizing and promoting superior domestic technologies and patented products. Only one institution receives the President’s Award annually, making Deepson Bio’s achievement notably meaningful. Winning products are currently on display at COEX in Seoul until December 6th.
Deepson Bio’s award-winning technology centers around a patented ultrasonic device (patent number 10-2317379,inventor: Gujin Jeong) designed to stimulate the brain’s lymphatic system and facilitate the removal of waste products,including beta-amyloid – a key factor in the progress of dementia. The company initially received the Presidential Award for this technology in 2021.
This non-invasive,non-pharmacological approach offers a potential advantage over existing dementia treatments by minimizing risks such as brain-blood barrier disruption,allergic reactions,and cerebral hemorrhage. Deepson Bio believes the technology holds promise for treating a range of degenerative brain diseases, including normal pressure hydrocephalus.
Building on this technology, Deepson Bio has independently developed “Neuclare,” a medical device for dementia treatment. The company has completed exploratory clinical trials and recently received approval from the Ministry of Food and Drug Safety to begin confirmatory clinical trials. These trials are slated to take place at seven leading hospitals across south Korea: Seoul National University Bundang Hospital, Hallym University Dongtan Sacred Heart Hospital, Ewha Womans University Mokdong Hospital, Ewha Womans University seoul Hospital, Soonchunhyang University Cheonan hospital, Inha University Hospital, and Catholic University St. Vincent Hospital.
“Receiving this Presidential Award is the result of official recognition of the potential of ultrasound devices for dementia treatment to change the paradigm of dementia treatment solutions,” said Lee Dong-hyeok, CEO of Deepson Bio. “We will accelerate commercialization by quickly completing the ongoing confirmatory clinical trial of Nuclair,while also accelerating our entry into overseas dementia treatment markets such as the United States and Japan.”
